Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms - Grünwald, Viktor; Powles, Thomas; Eto, Masatoshi; Kopyltsov, Evgeny; Rha, Sun Young; Porta, Camillo; Motzer, Robert; Hutson, Thomas E.; Méndez-Vidal, María José; Hong, Sung-Hoo; Winquist, Eric; Goh, Jeffrey C.; et al. (Frontiers in Oncology, 2024)